Clinical Trial Update: A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This entry describes an early-phase, single-arm, single-center trial evaluating bridging GPRC5D/CD3 bispecific antibody treatment followed by BCMA CAR-T cell th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T Cell Therapy
• GPRC5D/CD3 bispecific antibody

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING